Cargando…
Clusterin Part B /
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. In this Part B volume, outstanding and original reviews provide an overview and synthesis of the latest thoughts and findings relating to Clusterin. Chapters include CLU Gene express...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic,
2010.
|
| Colección: | Advances in cancer research,
v. 105 |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; Advances in Cancer Research; Copyright; Contents; Contributors; Chapter 1: Clusterin (CLU) and Prostate Cancer; I. Introduction; II. Briefly About Clinically Relevant Human PCa; III. CLU Signaling in Normal and Transformed Cell Lines; IV. CLU Expression in Human PCa; V. Castration Resistant and Metastatic PCa: The Challenge of CLU Antisense Therapy; VI. Chemoprevention of PCa: A Role for CLU in the Mechanism of Action of GTCs; VII. CLU as Tumor Modulator: Is CLU a Novel Tumor Suppressor Gene?; VIII. Conclusions; Acknowledgments; References
- Chapter 2: The Role of Clusterin (CLU) in Malignant Transformation and Drug Resistance in Breast CarcinomasI. Introduction; II. Localization of CLU in Breast Carcinomas; III. Relationship Between Cytoplasmic CLU and Apoptosis in Breast Carcinomas; IV. Role of CLU in Tumorigenesis and Progression of Breast Carcinomas; V. Prognostic Significance of CLU Expression in Breast Carcinomas; VI. CLU and Resistance to Treatment in Breast Carcinomas; VII. Conclusions; Acknowledgments; References; Chapter 3: CLU and Colon Cancer. The Dual Face of CLU: From Normal to Malignant Phenotype
- I. Introduction: Genes and Proteins in Colorectal CancerII. Genetic Instability and Control of DNA Damage: DNA Double-Strand Breaks Repair; III. Clonal Expansion: Apoptosis Inhibition; IV. CLU in Colorectal Cancer Progression: sCLU and Apoptosis Escape; V. CLU as a New Biomarker for Colon Cancer Screening; VI. Conclusions and Future Perspectives; References; Chapter 4: Clusterin (CLU) and Lung Cancer; I. Introduction; II. Carcinogenesis; III. Progression/Metastasis; IV. Treatment; V. CLU Expression and Prognosis in Patients with Lung Cancer; VI. Conclusions; Acknowledgments; References
- Chapter 5: Clusterin and ChemoresistanceI. Introduction; II. Association of sCLU with Chemoresistance; III. Association of sCLU with Multidrug Resistance; IV. Association of sCLU with Resistance to Irradiation and Oxidative Stress; V. Association of sCLU with Progressive Tumors; VI. Association of sCLU with Resistance to Targeted Therapy (TNF, FAS, TRAIL, HDAC Inhibitors, Herceptin); VII. Induction by Genotoxic and Oxidative Stresses; VIII. Mechanism of Induction of and Cytoprotection by CLU; IX. Strategies to Blockade CLU for Chemosensitization in Cancer Cells; References
- Chapter 6: CLU ""In and Out"": Lookingfor a LinkI. Introduction; II. Normal and Cancer Microecosystem; III. Microenvironment Effects on CLU Expression (the ""IN"" Effect); IV. sCLU Effects on Microenvironment (the ""OUT"" Effect): Up- and Downstream Signals; V. Conclusions and Future Perspectives; References; Chapter 7: Regulation of CLU Gene Expression by Oncogenes and Epigenetic Factors: Implications for Tumorigenesis; I. Introduction; II. Regulation of CLU Expression by Transforming Oncogenes: Early Evidence; III. Regulation of CLU Expression by Protooncogenic Transcription Factors